Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „avelumab“
Suchtreffer
Begriffe & Kennungen
Bavencio · 4.8 · Hepatotoxicity (in combination with axitinib) In patients treated with avelumab in combination with axitinib,
Eintrag öffnenBavencio · 4.8 · Immune-mediated adrenal insufficiency did not lead to discontinuation of avelumab in any patient. Eight (88.9%
Eintrag öffnenBavencio · 4.8 · Immune-mediated colitis In patients treated with avelumab as monotherapy, 1.5% (31/2 082) of patients develope
Eintrag öffnenBavencio · 4.8 · Immune-mediated endocrinopathies Thyroid disorders In patients treated with avelumab as monotherapy, 6.7% (140
Eintrag öffnenBavencio · 4.8 · Immune-mediated hepatitis In patients treated with avelumab as monotherapy, 1.0% (21/2 082) of patients develo
Eintrag öffnenBavencio · 4.8 · Immune-mediated myocarditis In patients treated with avelumab as monotherapy, immune-mediated myocarditis occu
Eintrag öffnenBavencio · 4.8 · Immune-mediated nephritis and renal dysfunction In patients treated with avelumab as monotherapy, immune-media
Eintrag öffnenBavencio · 4.8 · Immune-mediated pancreatitis In patients treated with avelumab as monotherapy, immune-mediated pancreatitis oc
Eintrag öffnenBavencio · 4.8 · Immune-mediated pneumonitis In patients treated with avelumab as monotherapy, 1.3% (28/2 082) of patients deve
Eintrag öffnenBavencio · 4.8 · Immune-mediated pneumonitis did not lead to discontinuation of avelumab in any patient. All 3 patients with im
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 2.7% (13/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 24.7% (121/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 6.3% (31/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, Type 1 diabetes mellitus without an alternativ
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, immune-mediated nephritis occurred in 0.4% (2/
Eintrag öffnenBavencio · 4.8 · Table 2: Adverse reactions in patients treated with avelumab as monotherapy
Eintrag öffnenBavencio · 4.8 · Table 3: Adverse reactions in patients treated with avelumab in combination with axitinib
Eintrag öffnenBavencio · 4.8 · The most common adverse reactions with avelumab were fatigue (30.0%), nausea (23.6%), diarrhoea (18.5%), const
Eintrag öffnenBavencio · 4.8 · The safety of avelumab as monotherapy has been evaluated in 2 082 patients with solid tumours including metast
Eintrag öffnenBavencio · 4.8 · The safety of avelumab in combination with axitinib has been evaluated in 489 patients with advanced RCC recei
Eintrag öffnen